B-specific: B-cell related gene and protein markers with prognostic and therapeutic value for CVD

The B-specific consortium aims to identify and target specific B-cell subsets to develop personalized therapies for atherosclerosis and improve cardiovascular disease risk assessment and management.

Subsidie
€ 4.006.599
2023

Projectdetails

Introduction

Atherosclerosis is the major underlying condition of cardiovascular disease (CVD) and one of the leading causes of mortality. Rupture or erosion of atherosclerotic lesions can lead to acute cardiovascular events, such as myocardial infarction and stroke. This makes biomarkers to diagnose patients at risk for these events and develop tailored preventive interventions an urgent need.

Background

Although atherosclerosis is a chronic inflammatory disease, clinical investigation of the adaptive immune system as a potential rheostat for disease development has been limited.

Objectives

The B-specific consortium aims to classify and mitigate the risk of CVD by:

  1. Generating novel types of genetic data.
  2. Defining novel prognostic and therapeutic targets attained from our recent discovery of a specific B-cell subset.

Methodology

We will employ state-of-the-art technology, including:

  • Single cell RNA sequencing
  • BCR repertoire analysis
  • Mass spectrometry-based identification of autoantigens in CVD patient material

With access to large population-based cohorts (FIMCOD, ERGO Study) spanning healthy adults of 40-105 years of age, we aim to:

  • Assess the prognostic value of circulating B cell subsets and antibodies in (sub)clinical atherosclerosis.
  • Investigate the contribution of genetic disposition.

Analysis

Using the extensive genomics data of the ERGO Study, we will be able to determine causal links between the prognostic indicators and disease progression by applying Mendelian Randomization experiments. We will confirm these relationships in ex vivo and in vivo models of atherosclerosis.

Expected Outcomes

Based on these findings, B-specific aims to develop at least one proof-of-concept therapy targeting specific B cells.

Dissemination

B-specific will implement an active open science platform. In combination with a targeted dissemination approach to healthcare professionals, we aim to impact cardiology practice and provide important new means of patient stratification and treatment options.

Financiële details & Tijdlijn

Financiële details

Subsidiebedrag€ 4.006.599
Totale projectbegroting€ 4.006.599

Tijdlijn

Startdatum1-10-2023
Einddatum30-9-2027
Subsidiejaar2023

Partners & Locaties

Projectpartners

  • UNIVERSITEIT LEIDENpenvoerder
  • LUNDS UNIVERSITET
  • KATHOLIEKE UNIVERSITEIT LEUVEN
  • ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM
  • INNOVATION ACTA SRL
  • HELMHOLTZ-ZENTRUM DRESDEN-ROSSENDORF EV

Land(en)

NetherlandsSwedenBelgiumItalyGermany

Vergelijkbare projecten binnen EIC Pathfinder

EIC Pathfinder

MultiomIcs based Risk stratification of Atherosclerotic CardiovascuLar disEase

The MIRACLE project aims to develop advanced multiomics-based risk prediction models for atherosclerotic cardiovascular disease by integrating genetic data and biomarkers for improved early diagnosis and treatment.

€ 4.000.000
EIC Pathfinder

Human Antibody-enabled Cardiovascular Personalized Theranosis

ABCardionostics aims to develop a multi-marker PET/MRI system using human antibodies to personalize treatment and improve diagnosis of atherosclerosis in vulnerable patients.

€ 3.639.665
EIC Pathfinder

Cardiogenomics meets Artificial Intelligence: a step forward in arrhythmogenic cardiomyopathy diagnosis and treatment

The project aims to integrate genomics, proteomics, and structural analyses to clarify genotype-phenotype relationships in arrhythmogenic cardiomyopathy, paving the way for novel therapies.

€ 3.740.868
EIC Pathfinder

A Multi-Omics Approach for Novel Drug Targets, Biomarkers and Risk Algorithms for Myocardial Infarction

TargetMI aims to rapidly discover novel drug targets and biomarkers for myocardial infarction using a high-throughput multi-omic approach on 1000 samples, enhancing clinical risk prediction and translation.

€ 3.999.840
EIC Pathfinder

Comprehensive Analysis of RBM20-induced Dilated Cardiomyopathies using Omics Approaches and Repair Interventions

CARDIOREPAIR aims to identify and therapeutically target RBM20 mutations in dilated cardiomyopathy using high-throughput genomics and bioengineering to improve heart health outcomes.

€ 4.349.410

Vergelijkbare projecten uit andere regelingen

ERC Starting...

The function of B cells in myocardial infarction-accelerated atherosclerosis

This project aims to investigate glucocorticoid signaling in B cells post-myocardial infarction to identify therapeutic targets for preventing accelerated atherosclerosis in cardiovascular disease.

€ 1.475.638
ERC Consolid...

Single cEll guided polygeniC Risk prEdicTion of ASCVD

This project aims to develop innovative polygenic risk models for atherosclerotic cardiovascular disease by leveraging genetic data and mechanistic insights to improve risk prediction and prevention.

€ 2.000.000
ERC Starting...

The extracellular matrix as a mediator of cell-cell communication in cardiovascular inflammation

The project aims to explore the extracellular matrix proteome in atherosclerosis and myocardial infarction to identify novel therapeutic targets for individualized treatment strategies.

€ 1.495.750
ERC Proof of...

Moving from whole genome cfDNA methylation to a PCR-based liquid biopsy assay for detecting high-risk atherosclerotic plaques

The U-BiomarCARE project aims to develop a PCR-based method to detect plaque-specific DNA methylation in plasma, enabling timely diagnosis of coronary artery disease in both men and women.

€ 150.000
ERC Starting...

Prognostic assessment of valvular aortic disease treatment coupling Immunological and biomechanical profiles

Protego aims to develop a predictive methodology combining immunological and biomechanical profiles to optimize treatment timing and outcomes for patients with aortic valve diseases, reducing complications.

€ 1.498.295